Immunological Characterization of Circulating Osteoprotegerin/Osteoclastogenesis Inhibitory Factor: Increased Serum Concentrations in Postmenopausal Women with Osteoporosis
- 1 April 1999
- journal article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 14 (4) , 518-527
- https://doi.org/10.1359/jbmr.1999.14.4.518
Abstract
Osteoprotegerin (OPG)/osteoclastogenesis inhibitory factor (OCIF) is a soluble member of the tumor necrosis factor receptor family of proteins and plays an important role in the negative regulation of osteoclastic bone resorption. Whether OPG/OCIF circulates in human blood and how its level changes under pathological conditions is not known. To address these issues, a panel of monoclonal antibodies was generated against recombinant OPG/OCIF and screened for reactivity with solid-phase monomeric and homodimeric forms of the recombinant protein. Antibodies that showed high affinity for both forms of OPG/OCIF and those that selectively recognized the homodimer were identified, enabling development of two types of sensitive enzyme-linked immunosorbent assay (ELISA): one that detects both forms of OPG/OCIF equally and one specific for the homodimer. Characterization of circulating OPG/OCIF with these ELISAs revealed that the protein exists in human serum mainly in the monomeric form. The serum concentration of OPG/OCIF increased with age in both healthy Japanese men and women, and was significantly higher in postmenopausal women with osteoporosis than in age-matched controls. Within the osteoporotic group, serum OPG/OCIF concentrations were higher in patients with low bone mass. Serum OPG/OCIF concentrations were also significantly increased in those postmenopausal women with a high rate of bone turnover, as determined by increased serum bone-specific alkaline phosphatase and urinary excretion of pyridinoline and deoxypyridinoline. The results suggested that circulating OPG/OCIF levels are regulated by an age-related factor(s) and that the increased serum concentration may reflect a compensative response to enhanced osteoclastic bone resorption and the resultant bone loss rather than a cause of osteoporosis.Keywords
This publication has 32 references indexed in Scilit:
- Transforming Growth Factor-β Stimulates the Production of Osteoprotegerin/Osteoclastogenesis Inhibitory Factor by Bone Marrow Stromal CellsJournal of Biological Chemistry, 1998
- Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and ActivationCell, 1998
- Characterization of Structural Domains of Human Osteoclastogenesis Inhibitory FactorPublished by Elsevier ,1998
- Regulation of Osteoclast FunctionJournal of Bone and Mineral Research, 1997
- Pycnodysostosis, a Lysosomal Disease Caused by Cathepsin K DeficiencyScience, 1996
- Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosisJournal of Bone and Mineral Research, 1996
- Preparation of an activity-inhibiting monoclonal antibody against human placental aromatase cytochrome P450Steroids, 1996
- Mutations at the mouse microphthalmia locus are associated with defects in a gene encoding a novel basic-helix-loop-helix-zipper proteinCell, 1993
- The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor geneNature, 1990
- Continuous cultures of fused cells secreting antibody of predefined specificityNature, 1975